Stemline B V — Elzonris EMA EPAR public assessment report (EMEA/H/C/005031, 2021)
Stemline B V · 2021 · EMA EPAR public assessment report
Report summary
The EMA's assessment of Elzonris (tagraxofusp) for blastic plasmacytoid dendritic cell neoplasm (BPDCN) led to marketing authorization under exceptional circumstances for first-line adult treatment. This decision, following an accelerated assessment and re-examination, recognized the unmet medical need for this rare, aggressive hematologic malignancy. The report details the drug's chemical, pharmaceutical, and biological aspects, including manufacturing and quality control. Preclinical studies demonstrated efficacy in BPDCN and AML models and identified toxicological profiles. Pharmacokinetic and pharmacodynamic analyses linked higher drug exposure to improved response but also increased safety risks like capillary leak syndrome. Clinical efficacy was established in first-line BPDCN patients, with a 53.8% complete response rate in the pivotal study. While the safety profile is non-trivial, the benefits, especially bridging patients to stem cell transplantation, outweigh the risks for previously untreated individuals, despite unestablished efficacy in relapsed/refractory settings.
Key findings — cited to the page
| AST increased (Grade ≥3 TEAE) | 24.1% | · p.201 |
| Grade ≥3 TEAEs | 80.9% | · p.201 |
| ALT increased (Grade ≥3 TEAE) | 24.8% | · p.201 |
| anaemia (Grade ≥3 TEAE) | 19.9% | · p.201 |
| thrombocytopenia (Grade ≥3 TEAE) | 31.2% | · p.201 |
| Mean age of BPDCN patients | 60 and 70 years | · p.11 |
| Annual incident cases of BPDCN | 1000 | Europe · p.11 |
| CHMP final opinion date (re-examination) | 12 November 2020 | · p.10 |
| Skin lesions as only extramedullary manifestation in BPDCN | 50% | · p.12 |
| Skin involvement in BPDCN patients | 90% | · p.12 |
| Lymph node involvement at presentation in BPDCN | 40%-50% | · p.12 |
| BPDCN as percentage of hematologic cancers | 0.44% | · p.11 |
Source: Stemline B V ↗ · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →